Has Michael Rogawski, MD received payments from drug or device companies?

Yes. Drug and device makers reported $155,553 in general payments to Michael Rogawski, MD across 40 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Michael Rogawski, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Michael Rogawski, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Michael Rogawski, MD

Neurology · Sacramento, CANPI 1538357033

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $115,918 of the $155,553 with a category attached, or 74.5%. 12 manufacturers reported payments, led by Immedica Pharma US, Inc. at 45.6% of the total. Reporting peaked in 2023 at $55,279 and has fallen 79.9% since, to $11,084 in 2025. Among neurology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$155,553in general payments, 2019–2025

Across 40 payments — averaging $3888.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Immedica Pharma US, Inc.$71K
H. Lundbeck A S$20K
Aquestive Therapeutics, Inc.$15K
SK Life Science, Inc.$12K
Jazz Pharmaceuticals Inc.$8K
Merck$7K
plus $21K from 6 others

$245,502in research payments, 2019–2025

Across 9 payments — averaging $27,278 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Mallinckrodt Hospital Products Inc.$193K
Aquestive Therapeutics, Inc.$27K
Mallinckrodt Enterprises LLC$26K

What the payments were for

Consulting fees$115,91875%
Speaking & faculty fees$16,52511%
Travel & lodging$22,10414%
Food & beverage$1,0061%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Immedica Pharma US, Inc.	7	$70,890
H. Lundbeck A S	4	$20,067
Aquestive Therapeutics, Inc.	5	$15,274
SK Life Science, Inc.	7	$12,478
Jazz Pharmaceuticals Inc.	2	$8,310
Merck	7	$7,128
Bristol Myers Squibb	2	$6,450
Eisai Inc.	2	$6,420
UCB SA	1	$4,481
Aadi Bioscience, Inc.	1	$3,763
UCB, Inc.	1	$173
Neurelis, Inc.	1	$120

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

ZTALMY$16,960
LIBERVANT$12,300
XCOPRI$7,753
Fintepla$4,481
SYMPAZAN$2,900
Epidiolex$2,000
Fycompa$1,620
VALTOCO$120

How this compares

$155,553 in reported general payments places this provider in the 95th percentile of 1,996 neurology providers in California.

See all neurology providers in California →

Medicare billing

Part B allowed, 2024

$6,467

Medicare patients

Services billed

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Nurtec OdtRimegepant Sulfate	70	$107,502
QuliptaAtogepant	33	$40,838
Emgality PenGalcanezumab-Gnlm	30	$21,925
Aimovig AutoinjectorErenumab-Aooe	18	$20,083
Ajovy AutoinjectorFremanezumab-Vfrm	15	$16,121
Frovatriptan Succinate	23	$7,136
Sumatriptan Succinate	48	$2,157
Amitriptyline Hcl	63	$1,254
Candesartan Cilexetil	12	$698
Prochlorperazine Maleate	32	$295
Ketorolac Tromethamine	22	$284
Topiramate	14	$174

Paid to pharmacies, not to this prescriber.

Other neurology in Sacramento

Lin ZhangSacramento$328K
Andrew BlumenfeldCarlsbad$4.9M
Khashayar DashtipourLoma Linda$3.3M
Regina BerkovichWest Hollywood$3M
Daniel BandariNewport Beach$2.6M
Perry ShiehLos Angeles$2.4M
Sandeep ThakkarIrvine$2M
David LiebeskindLos Angeles$1.9M
Jack SchimCarlsbad$1.7M
Parshaw DorrizMission Viejo$1.5M

See the full list for California →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →